Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229458082> ?p ?o ?g. }
- W4229458082 endingPage "e414" @default.
- W4229458082 startingPage "e403" @default.
- W4229458082 abstract "Elotuzumab plus lenalidomide and dexamethasone has shown improved progression-free and overall survival versus lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. We aimed to assess these regimens in patients with newly diagnosed multiple myeloma who are ineligible for haematopoietic stem-cell transplantation (HSCT).ELOQUENT-1 is an open-label, multicentre, randomised, phase 3 trial conducted at 185 hospitals, oncology practices, and research centres in 19 countries. Eligible patients were aged 18 years or older with newly diagnosed, untreated, symptomatic myeloma and not candidates for high-dose therapy plus HSCT, and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower. Patients were randomly assigned (1:1) to receive elotuzumab plus lenalidomide and dexamethasone or lenalidomide and dexamethasone using an interactive voice response system, stratified by the International Staging System (ISS; stage I-II vs III), age (<75 years vs ≥75 years), and ECOG performance status (0 vs 1-2). Patients in the elotuzumab plus lenalidomide and dexamethasone group received elotuzumab administered intravenously at 10 mg/kg on days 1, 8, 15, and 22 during cycles 1 and 2, days 1 and 15 during cycles 3-18, and then at 20 mg/kg on day 1 for subsequent cycles. In both treatment groups, patients received 25 mg lenalidomide orally on days 1-21 of each cycle and 40 mg dexamethasone on days 1, 8, 15, and 22 of each cycle. The primary endpoint was progression-free survival, as per the primary definition from European Society for Blood and Marrow Transplantation criteria in all randomly assigned patients (intention-to-treat population). This study is registered with ClinicalTrials.gov, NCT01335399 (completed).Between Aug 4, 2011, and June 19, 2014, 748 patients were randomly assigned (374 in each treatment group) and 742 patients received treatment (333 (90%) of 371 in the elotuzumab plus lenalidomide and dexamethasone group vs 339 (91%) of 371 in the lenalidomide and dexamethasone group discontinued treatment). The median age of patients was 73·0 years (IQR 69·0-78·0), 294 (39%) patients were 75 years or older. Most patients were White (711 [95%]) and male (412 [55%]). At a minimum follow-up of 65·3 months, the median progression-free survival was not significantly different between the groups: 31·4 months (95% CI 26·2-36·8) in the elotuzumab plus lenalidomide and dexamethasone group versus 29·5 months (23·5-34·3) in the lenalidomide and dexamethasone group (HR 0·93, 95·71% CI 0·77-1·12; stratified log-rank p=0·44). The median follow-up was 70·6 months (IQR 35·1-79·2). The most common grade 3-4 treatment-related adverse event was neutropenia (64 [17%] of 371 vs 79 [21%] of 371). Study drug toxicity was the reported cause of death in five (1%) versus four (1%) patients.Elotuzumab plus lenalidomide and dexamethasone did not significantly improve progression-free survival versus lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for HSCT. Although these data contribute to the treatment landscape, further research is needed to find ways to improve treatments in the front-line setting.Bristol Myers Squibb." @default.
- W4229458082 created "2022-05-11" @default.
- W4229458082 creator A5002340653 @default.
- W4229458082 creator A5003280424 @default.
- W4229458082 creator A5012405296 @default.
- W4229458082 creator A5018685925 @default.
- W4229458082 creator A5022522496 @default.
- W4229458082 creator A5023276777 @default.
- W4229458082 creator A5023517351 @default.
- W4229458082 creator A5029159537 @default.
- W4229458082 creator A5030524608 @default.
- W4229458082 creator A5033439690 @default.
- W4229458082 creator A5035520823 @default.
- W4229458082 creator A5043490010 @default.
- W4229458082 creator A5043526996 @default.
- W4229458082 creator A5045814742 @default.
- W4229458082 creator A5049711954 @default.
- W4229458082 creator A5050961257 @default.
- W4229458082 creator A5051306233 @default.
- W4229458082 creator A5055916434 @default.
- W4229458082 creator A5062322697 @default.
- W4229458082 creator A5065238694 @default.
- W4229458082 creator A5071466957 @default.
- W4229458082 creator A5071926851 @default.
- W4229458082 creator A5073964632 @default.
- W4229458082 creator A5077897003 @default.
- W4229458082 creator A5081564280 @default.
- W4229458082 creator A5088174608 @default.
- W4229458082 date "2022-06-01" @default.
- W4229458082 modified "2023-10-17" @default.
- W4229458082 title "Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial" @default.
- W4229458082 cites W1978377409 @default.
- W4229458082 cites W1988265934 @default.
- W4229458082 cites W2004543856 @default.
- W4229458082 cites W2020298011 @default.
- W4229458082 cites W2037050131 @default.
- W4229458082 cites W2044436186 @default.
- W4229458082 cites W2086278185 @default.
- W4229458082 cites W2128644254 @default.
- W4229458082 cites W2140579395 @default.
- W4229458082 cites W2141105112 @default.
- W4229458082 cites W2201190784 @default.
- W4229458082 cites W2343386476 @default.
- W4229458082 cites W2460376887 @default.
- W4229458082 cites W2494994085 @default.
- W4229458082 cites W2567188480 @default.
- W4229458082 cites W2625253716 @default.
- W4229458082 cites W2732548543 @default.
- W4229458082 cites W2769593282 @default.
- W4229458082 cites W2796970920 @default.
- W4229458082 cites W2890436368 @default.
- W4229458082 cites W2900068404 @default.
- W4229458082 cites W2919022600 @default.
- W4229458082 cites W2947874495 @default.
- W4229458082 cites W2984568395 @default.
- W4229458082 cites W3032976214 @default.
- W4229458082 cites W3082053425 @default.
- W4229458082 cites W3083502363 @default.
- W4229458082 cites W3136388199 @default.
- W4229458082 doi "https://doi.org/10.1016/s2352-3026(22)00103-x" @default.
- W4229458082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35550060" @default.
- W4229458082 hasPublicationYear "2022" @default.
- W4229458082 type Work @default.
- W4229458082 citedByCount "16" @default.
- W4229458082 countsByYear W42294580822022 @default.
- W4229458082 countsByYear W42294580822023 @default.
- W4229458082 crossrefType "journal-article" @default.
- W4229458082 hasAuthorship W4229458082A5002340653 @default.
- W4229458082 hasAuthorship W4229458082A5003280424 @default.
- W4229458082 hasAuthorship W4229458082A5012405296 @default.
- W4229458082 hasAuthorship W4229458082A5018685925 @default.
- W4229458082 hasAuthorship W4229458082A5022522496 @default.
- W4229458082 hasAuthorship W4229458082A5023276777 @default.
- W4229458082 hasAuthorship W4229458082A5023517351 @default.
- W4229458082 hasAuthorship W4229458082A5029159537 @default.
- W4229458082 hasAuthorship W4229458082A5030524608 @default.
- W4229458082 hasAuthorship W4229458082A5033439690 @default.
- W4229458082 hasAuthorship W4229458082A5035520823 @default.
- W4229458082 hasAuthorship W4229458082A5043490010 @default.
- W4229458082 hasAuthorship W4229458082A5043526996 @default.
- W4229458082 hasAuthorship W4229458082A5045814742 @default.
- W4229458082 hasAuthorship W4229458082A5049711954 @default.
- W4229458082 hasAuthorship W4229458082A5050961257 @default.
- W4229458082 hasAuthorship W4229458082A5051306233 @default.
- W4229458082 hasAuthorship W4229458082A5055916434 @default.
- W4229458082 hasAuthorship W4229458082A5062322697 @default.
- W4229458082 hasAuthorship W4229458082A5065238694 @default.
- W4229458082 hasAuthorship W4229458082A5071466957 @default.
- W4229458082 hasAuthorship W4229458082A5071926851 @default.
- W4229458082 hasAuthorship W4229458082A5073964632 @default.
- W4229458082 hasAuthorship W4229458082A5077897003 @default.
- W4229458082 hasAuthorship W4229458082A5081564280 @default.
- W4229458082 hasAuthorship W4229458082A5088174608 @default.
- W4229458082 hasConcept C126322002 @default.
- W4229458082 hasConcept C141071460 @default.
- W4229458082 hasConcept C143998085 @default.
- W4229458082 hasConcept C168563851 @default.
- W4229458082 hasConcept C203092338 @default.